Archives

  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01

    • WM-8014: Selective KAT6A/B Inhibitor for Epigenetic Research

    2026-02-16

    WM-8014: Selective KAT6A/B Inhibitor for Epigenetic Research

    Executive Summary: WM-8014 is a potent, reversible, and competitive inhibitor of KAT6A and KAT6B, acting at nanomolar concentrations (IC50 8–28 nM) and displaying high selectivity over KAT5 and KAT7 (IC50 ≥224 nM) (APExBIO). It functions by competitively binding the acetyl-CoA site within the MYST domain, mimicking natural substrate interactions (bioRxiv 2025). In cellular models, WM-8014 induces robust cell cycle arrest and senescence via the p16INK4A–p19ARF pathway without eliciting general cytotoxicity (bioRxiv 2025). In vivo, it reduces KRAS G12V-driven liver overgrowth in zebrafish while sparing normal tissue, supporting its use as a precision epigenetic tool. Solubility and protein binding constraints must be addressed for in vivo mouse applications, with WM-1119 recommended as an alternative (APExBIO).

    Biological Rationale

    Histone lysine acetyltransferases (KATs) modulate chromatin accessibility and gene expression via acetylation of lysine residues on histone tails. KAT6A (MOZ) and KAT6B (MORF/QKF) are members of the MYST family and are frequently dysregulated in cancer and developmental disorders (bioRxiv 2025). Their enzymatic activity is essential for cell proliferation, cell cycle progression, and maintenance of stem cell programs. Targeting KAT6A/B has emerged as a promising epigenetic strategy to induce oncogene-induced senescence and suppress tumorigenesis (Contrast: This article details WM-8014's unique competitive mechanism and selectivity profile, building on general overviews.).

    Mechanism of Action of WM-8014

    WM-8014 is a highly potent, reversible, and competitive inhibitor of KAT6A (IC50 8 nM), KAT6B (IC50 28 nM), with significantly reduced potency against KAT5 (IC50 224 nM) and KAT7 (IC50 342 nM) (APExBIO). It binds directly to the acetyl-CoA binding site within the MYST domain of its targets. The acyl sulfonyl hydrazide core of WM-8014 forms hydrogen bonds analogous to the diphosphate group of acetyl-CoA, competitively inhibiting substrate access (bioRxiv 2025). This precise binding underlies its selectivity and competitive inhibition profile. Unlike pan-KAT inhibitors, WM-8014 minimizes off-target effects on other acetyltransferases and does not cause global cytotoxicity at effective concentrations (Contrast: This section clarifies selectivity and mechanism beyond efficacy summaries.).

    Evidence & Benchmarks

    • WM-8014 inhibits KAT6A with an IC50 of 8 nM (biochemical assay, 25°C, pH 7.4) (APExBIO).
    • Selective inhibition of KAT6B is achieved at an IC50 of 28 nM under similar assay conditions (APExBIO).
    • KAT5 and KAT7 inhibition occurs at 224 nM and 342 nM respectively, confirming selectivity for KAT6A/B (APExBIO).
    • RNA-seq of WM-8014-treated MEFs shows increased Cdkn2a (p16INK4A/p19ARF) mRNA and decreased Cdc6, a KAT6A target, after 24 h at 1 μM (bioRxiv 2025).
    • Cellular senescence is induced without general cytotoxicity, as shown by viability assays (MTT, 72 h, 1 μM) (bioRxiv 2025).
    • In zebrafish, WM-8014 at 1–10 μM reduces KRAS G12V-driven liver hyperplasia and S-phase entry, sparing normal liver growth (3 dpf, 28°C) (bioRxiv 2025).
    • WM-8014 is soluble in water up to 8–16 μM, and highly soluble in DMSO (≥76.1 mg/mL), but insoluble in ethanol (APExBIO).
    • Due to high plasma protein binding, in vivo efficacy in mouse models is limited; WM-1119 is recommended as an alternative (APExBIO).

    Applications, Limits & Misconceptions

    WM-8014 enables precise, non-cytotoxic induction of oncogene-induced senescence in cell-based and zebrafish models (Contrast: This article provides a more comprehensive, data-driven workflow versus scenario-based Q&A.). It is optimal for assays dissecting the p16INK4A–p19ARF senescence pathway, studying cell cycle arrest, and validating epigenetic drug targets in cancer biology research. However, its high plasma protein binding restricts use in murine in vivo studies. Long-term storage of WM-8014 solutions is not advised due to stability concerns.

    Common Pitfalls or Misconceptions

    • Not suitable for broad-spectrum KAT inhibition: WM-8014 is highly selective for KAT6A/B and does not inhibit all KAT family members at nanomolar concentrations.
    • Limited utility in mouse in vivo studies: High plasma protein binding impedes effective in vivo dosing in mice; use WM-1119 for such applications (APExBIO).
    • Solubility constraints: WM-8014 is insoluble in ethanol and poorly soluble in aqueous buffers above 16 μM; DMSO is recommended for stock solutions.
    • Senescence induction is context-dependent: Efficacy depends on the presence of intact p16INK4A–p19ARF signaling; loss-of-function mutations in these genes abrogate the response.
    • No direct cytotoxicity: WM-8014 does not induce apoptosis or general cytotoxicity at effective doses; its utility is in senescence and cell cycle arrest assays.

    Workflow Integration & Parameters

    For cell-based assays, WM-8014 is typically applied at 0.1–1 μM in DMSO (final DMSO ≤0.2%) for 24–72 h. RNA-seq and qPCR can be used to measure upregulation of Cdkn2a and downregulation of Cdc6 post-treatment. Senescence is confirmed via SA-β-gal staining or p16INK4A immunoblotting. For zebrafish models, 1–10 μM WM-8014 is added to embryo medium from 24 to 96 hpf at 28°C (bioRxiv 2025). Solutions should be freshly prepared and stored at -20°C; repeated freeze-thaw cycles are discouraged. For further details on precision epigenetic targeting, see this advanced mechanistic review (extends mechanistic context beyond this article).

    For purchasing, protocol details, or technical support, refer to the WM-8014 product page from APExBIO.

    Conclusion & Outlook

    WM-8014 is a validated, highly selective KAT6A/B inhibitor and a robust tool for dissecting epigenetic regulation of cell fate in cancer biology. Its competitive acetyl-CoA site inhibition, non-cytotoxic profile, and precise induction of oncogene-induced senescence set it apart as a research standard for p16INK4A–p19ARF pathway studies. Users should be aware of its solubility and in vivo limitations, and consider alternatives such as WM-1119 for murine models. Ongoing studies leveraging time-gated CRISPR screens and advanced omics will further expand WM-8014's utility in epigenetic drug discovery (bioRxiv 2025).